Chief Financial Officer · Avalo Therapeutics, Inc. · Avalo Therapeutics, Inc. — Restricted Stock Units
Side
M
Value
—
Shares
24.2K
Price
—
Executed
Mar 28, 2026
Disclosed
Mar 31, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Mar 28 executedMar 31, 2026 disclosed
AVTX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Sullivan Christopher Ryan filed this Form 4 reporting a option exercise of AVTX on Mar 28, 2026. It became public on Mar 31, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Sullivan Christopher Ryancik:0001810417
Issuer
Avalo Therapeutics, Inc.cik:0001534120
Revision history · 0
No field has changed since this record was first ingested.
